Top differentially expressed genes between patients with progressive disease and those with complete remission following the first course of treatment in different cancer types

Different treatment modalities might lead to partial or complete remission or progressive disease in patients with cancer. In the present study, based on transcriptomics data analysis, top 10 genes whose expression most significantly differ between patients with complete remission/response and patients with progressive disease, following the first course of treatment, were identified in different cancer types, namely, bladder urothelial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, brain lower grade glioma, lung adenocarcinoma, prostate adenocarcinoma and stomach adenocarcinoma. The majority of the identified genes in different cancer types were found to be highly understudied in the context of those cancer types. Besides, there does not seem to be any overlap in the top differentially expressed genes between different cancers, suggesting that genes/proteins associated with disease progression might be highly cancer type-dependent. Combined, findings from this study indicate the need for further research on the identified genes in given cancer types to better understand if or how their differential expression between cancer patients with complete response and patients with progressive disease clinically influence disease outcomes, with the ultimate aim of finding actionable targets to improve treatment success for patients with given malignancies.